A multicenter, randomized, controlled study of Shugan Xiaozhi Granules in the treatment of nonalcoholic fatty liver disease patients with abnormal ALT

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005716

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

therapy group:Shugan Xiaozhi Granules+behavioral therapy

Control group:behavioral therapy+Yi Shanfu

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for nonalcoholic fatty liver disease with abnormal ALT 2. TCM syndrome classification is: liver and gallbladder damp-heat, phlegm blocking blood stasis 3. Age 18-65 years old, no drinking history or drinking alcohol equivalent to ethanol <30 g/d for men and <20 for women g/d;

Exclusion criteria

Exclusion criteria: 1. It is complicated with Drug-induced liver injury, autoimmune hepatitis, viral hepatitis, alcoholic liver disease, liver cancer 2. It is complicated with Heart, brain, kidney, lung, blood, severe diabetic complications, thyroid dysfunction, metabolic and gastrointestinal serious primary diseases, or mental patients 3. Women who are breastfeeding, pregnant or planning to become pregnant 4. Abnormal transaminases greater than 5 times the upper limit of normal, and creatinine greater than the upper limit of normal

Design outcomes

Primary

Measure	Time frame
liver function;fasting blood sugar;uric acid;lipid profile;Body mass index;hepatobiliary ultrasound;	—

Countries

China

Contacts

Public ContactTong Guangdong

tgd755@163.com13603028208

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026